Sobi’s $50M bet on a rare disease drug pays off with a quick FDA nod

Sobi’s $50M bet on a rare disease drug pays off with a quick FDA nod

Source: 
Endpoints
snippet: 

Just 4 months after Sobi paid Novimmune $50 million in cash — and put $400 million up in milestones — for a rare disease drug called emapalumab, the FDA has followed up with a quick OK on marketing.